A multi-type HPV transmission model

Bulletin of Mathematical Biology

Volumn 70, Issue 8, 2008, Pages 2126-2176

  Elbasha, Elamin H ^a   Dasbach, Erik J ^a   Insinga, Ralph P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cervical intraepithelial neoplasia; Condylomata acuminata; Cost effectiveness analysis; Disease transmission; Herd immunity; Human papillomavirus; Nonlinear dynamics; Theoretical models; Uterine cervical neoplasms; Vaccines

Indexed keywords

WART VIRUS VACCINE;

AGE; ALPHAPAPILLOMAVIRUS; ARTICLE; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; FEMALE; HUMAN; IMMUNOLOGY; INCIDENCE; MALE; NONLINEAR SYSTEM; PATHOGENICITY; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SEX DIFFERENCE; STATISTICS; THEORETICAL MODEL; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VACCINATION; VIRUS INFECTION;

AGE FACTORS; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; MODELS, THEORETICAL; NONLINEAR DYNAMICS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SEX FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES;

EID: 55349129265     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-008-9338-x     Document Type: Article

References (89)

1. J.C. Abma F.L. Sonenstein 2001 Sexual activity and contraceptive practices among teenagers in the United States, 1988 and 1995 Nat. Center Health Stat. Vital Health Stat. 23 21 1 79
2. C. Aoyama J. Peters S. Senadheera 1998 Uterine cervical dysplasia and cancer: identification of c-myc status by quantitative polymerase chain reaction Diagn. Mol. Pathol. 7 324 330
3. B. Andersen 1996 Stress and quality of life following cervical cancer J. Nat. Cancer Inst. 21 65 70
4. Barnabas, R.V., Garnett, G.P., 2004. The potential public health impact of vaccines against human papillomavirus. In: Prendiville, W., Davies, P. (Eds.), The Clinical Handbook of Human Papillomavirus. Parthenon Publishing/Parthenon Medical Communications, Lancaster.
5. R.V. Barnabas P. Laukkanen P. Koskela 2006 Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses PLOS Med. 3 1 9
6. G. Bigras F. de Marval 2005 The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women Br. J. Cancer 93 575 581
7. F.X. Bosch S. de Sanjose 2003 Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality J. Natl. Cancer Inst. Monogr. 31 3 13
8. A.N. Burchell H. Richardson S.M. Mahmud H. Trottier P.P. Tellier J. Hanley 2006 Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada Am. J. Epidemiol. 163 534 543
9. P.E. Castle M. Schiffman M.C. Bratti A. Hildesheim R. Herrero 2004 A population-based study of vaginal human papillomavirus infection in hysterectomized women J. Infect. Dis. 190 458 467
10. Center on the Evaluation of Value and Risk in Health. 2006. The cost-effectiveness analysis registry [Internet]. (Boston), Tufts-New England Medical Center, ICRHPS. Available from: http://www.tufts-nemc.org/cearegistry/ (Accessed March 13, 2006).
11. Centers for Disease Control and Prevention. 2004. Prevention of genital human papillomavirus infection. Report to Congress, Washington DC, January.
12. H.W. Chesson J.M. Blandford T.L. Gift 2004 The estimated direct medical cost of sexually transmitted diseases among American youth, 2000 Perspect. Sex. Reprod. Health 36 11 19
13. J. Coste B. Cochand-Priollet P. De Cremoux 2003 Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening BMJ 326 733
14. M.E. Cruickshank L. Sharp G. Chambers 2002 Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia BJOG 109 579 581
15. D. De Aloysio L. Miliffi T. Iannicelli 1994 Intramuscular interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection Acta Obstet. Gynecol. Scand. 73 420 424
16. Eddy, D.M., 1980. Screening for Cancer: Theory, Analysis, and Design. Prentice-Hall, Englewood Cliffs.
17. D. Eddy 1990 Screening for cervical cancer Ann. Int. Med. 113 214 226
18. W.J. Edmunds G.F. Medley D.J. Nokes 1999 Evaluating the cost-effectiveness of vaccination programmes: a dynamic approach Stat. Med. 18 3263 3282
19. M. Brisson W.J. Edmunds 2003 Economic evaluation of vaccination programs: the impact of herd immunity Med. Decis. Mak. 23 76 82
20. E.H. Elbasha A.P. Galvani 2005 Vaccination against multiple types Math. Biosci. 197 88 117
21. E. Elbasha E. Dasbach R. Insinga 2007 Model for assessing human papillomavirus vaccination strategies Emerg. Infect. Dis. 13 28 41
22. M.F. Evans S.L. Mount B.G. Beatty 2002 Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia Mod. Pathol. 15 1339 1347
23. M.C. Fahs J. Mandelblatt C. Schechter C. Muller 1992 Cost effectiveness of cervical cancer screening for the elderly Ann. Int. Med. 117 520 527
24. G. Flannelly H. Langhan L. Jandial E. Mana M. Campbell H. Kitchener 1997 A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia Br. J. Obstet. Gynaecol. 104 718 722
25. D. Fryback E. Dasbach R. Klein 1993 Initial catalog of health-state quality factors Med. Dec. Mak. 13 89 102
26. G.P. Garnett R.M. Anderson 1993 Factors controlling the spread of HIV in heterosexual communities in developing countries: Patterns of mixing between age and sexual activity classes Philos. Trans. R. Soc. Lond. B 342 137 159
27. G.P. Garnett R.M. Anderson 1993 Contact tracing and the estimation of sexual mixing patterns: The epidemiology of gonoccal infections Sex. Transm. Dis. 20 181 191
28. G.P. Garnett R.M. Anderson 1994 Balancing sexual partnerships in age and activity stratified model of HIV transmission in heterosexual populations IMA J. Math. Appl. Med. Biol. 11 161 192
29. G.P. Garnett H. Waddell 2000 Public health paradoxes and the epidemiological impact of an HPV vaccine J. Clin. Virol. 19 101 111
30. G.P. Garnett J.P. Hughes R.M. Anderson B.P. Stoner S.O. Aral W.L. Whittington H.H. Handsfield K.K. Holmes 1996 The determination of the sexual mixing pattern of patients attending STD and other clinics in Seattle, USA, by contact tracing Sex. Transm. Dis. 23 248 257
31. A.R. Giuliano R. Harris R.L. Sedjo 2002 Incidence, prevalence, and clearance of type-speci...c human papillomavirus infections: The Young Women's Health Study J. Infect. Dis. 186 462 469
32. M. Gold P. Franks K. McCoy D. Fryback 1998 Toward consistency in cost-utilities analysis Med. Care 36 778 792
33. S.J. Goldie D. Grima M. Kohli T.C. Wright M.C. Weinstein E. Franco 2003 A comprehensive natural history model of human papillomavirus (HPV) infection and cervical cancer: Potential impact of and HPV 16/18 Vaccine Int. J. Cancer 106 896 904
34. S.J. Goldie M. Kohli D. Grima M.C. Weinstein T.C. Wright F.X. Bosch E. Franco 2004 Projected clinical benefits and cost-effectiveness of a human papllomavirus 16/18 vaccine J. Nat. Cancer Inst. 96 604 615
35. L. Gustafsson J. Ponten R. Bergstrom H.O. Adami 1997 International incidence rates of invasive cervical cancer before cytological screening Int. J. Cancer 71 159 165
36. T. Hammerschmidt A. Goertz S. Wagenpfeil 2003 Validation of health economic models: the example of EVITA Value Health 6 551 559
37. D. Harper E. Franco C. Wheeler D. Ferris D. Jenkins 2004 Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 1757 1765
38. H. Hethcote 1997 An age-structured model of pertussis transmission Math. Biosci. 145 89 136
39. M. Schuette H. Hethcote 1999 Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles Bull. Math. Biol. 61 1031 1064
40. G.Y.F. Ho R.D. Burk S. Klein 1995 Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia J. Natl. Cancer Inst. 87 1365 1371
41. H. Hoyer C. Scheungraber R. Kuehne-Heid 2005 Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting Int. J. Cancer 116 136 143
42. J.P. Hughes G.P. Garnett L.A. Koutsky 2002 The theoretical population level impact of a prophylactic human papilloma virus vaccine Epidemiology 13 631 639
43. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1995. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses, vol. 64. International Agency for Research on Cancer, Lyons.
44. Insinga, R.P., 2007. The natural history of low-grade cervical intraepithelial neoplasia. Manuscript in preparation.
45. R.P. Insinga E.J. Dasbach E.R. Myers 2003 The health and economic burden of genital warts in a set of private U.S. Health Plans Clin. Infect. Dis. 36 1397 1403
46. R.P. Insinga A.G. Glass B.B. Rush 2004 Pap screening in a U.S. health plan Cancer Epidemiol. Biomark. Prev. 13 355 360
47. R.P. Insinga A.G. Glass B.B. Rush 2004 Diagnoses and outcomes in cervical cancer screening: a population-based study Am. J. Obstet. Gynecol. 191 105 113
48. Insinga, R.P., Dasbach, E.J., Elbasha, E.H., 2006. Epidemiologic natural history and clinical outcomes of human papillomavirus (HPV) disease: a critical review of the literature in the development of an HPV dynamic transmission model. Manuscript in review.
49. R.P. Insinga E.J. Dasbach E.H. Elbasha K.-L. Liaw E. Barr 2007 Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: An evaluation from multiple analytic perspectives Cancer Epidemiol. Biomark. Prev. 16 4 709 715
50. C. Isacson T.D. Kessis L. Hedrick 1996 Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type Cancer Res. 56 669 674
51. M.V. Jacobs J.M. Walboomers P.J. Snijders F.J. Voorhorst R.H. Verheijen N. Fransen-Daalmeijer C.J. Meijer 2000 Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types Int. J. Cancer 87 221 227
52. V. Kataja K. Syrjanen R. Mantyjarvi 1989 Prospective follow-up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data Eur. J. Epidemiol. 5 1 7
53. H. Keshavarz S.D. Hillis B.A. Kieke 2002 Hysterectomy surveillance-United States, 1994-1999 MMWR CDC Surveill. Summ. 51 1 8
54. J. Kim T. Wright S. Goldie 2002 Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance JAMA 287 2382 2390
55. Kochanek, K.D., Murphy, S.L., Anderson, R.N., Scott, C., 2004. Deaths: Final data for 2002. National Vital Statistics Reports, vol. 53(5). National Center for Health Statistics, Hyattsville.
56. L.A. Koutsky K.A. Ault C.M. Wheeler D.R. Brown E. Barr 2002 A controlled trial of a human papillomavirus type 16 vaccine N. Engl. J. Med. 347 1645 1651
57. S.L. Kulasingam E.R. Myers 2003 Potential health and economic impact of adding a human papillomavirus vaccine to screening programs JAMA 290 781 789
58. Kulasingam, S., Harper, D., Tosteson, A., Myers, E., 2002. Impact of quality-of-life assumptions on cost-effectiveness of cervical cancer screening. In 20th International Papillomavirus Conference, Paris, France, October 2002 (abstract 121).
59. Lauman, E., Gagnon, J., Michael, R., Michaels, S., 1994. The Social Organization of Sexuality. University of Chicago Press, Chicago.
60. K. Matsumoto T. Yasugi A. Oki 2006 IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia Cancer Lett. 231 309 313
61. McCrory, D., Mather, D., Bastain, L., Datta, S., Hasselblad, V., Hickey, J., Myers, E., Nanda, K., February 1999. Evaluation of cervical cytology. Evidence Report/Technology Assessment No. 5 (Prepared by Duke University under Contract No. 290-97-0014). AHCPR Publication No. 99-E010.
62. J.A. McIntyre P.A. Leeson 2006 GardasilTM: anti-papillomavirus vaccine Drugs Future 3 97 100
63. Medstat. 2001. MarketScan R database, Thomson Medstat. Ann Arbor, MI. Rockville, MD: Agency for Health Care Policy and Research. February 1999. Available: http://www.ahrq.gov/clinic/epcsums/cervsumm.htm.
64. Michael, R., Gagnon, J., Lauman, E., Kolata, G., 1994. Sex in America. Little, Brown & Co, Inc., New York.
65. R. Michael J. Wadsworth J. Feinleib A. Johnson E. Lauman K. Wellings 1998 Private sexual behavior, public opinion, and public health policy related to sexualy transmitted diseases: a US-British comparison Am. J. Public Health 88 749 754
66. M.F. Mitchell D. Schottenfeld G. Tortolero Luna S.B. Cantor R. Richards Kortum 1998 Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta analysis Obstet. Gynecol. 91 626 631
67. E. Myers D. McCrory K. Nanda L. Bastian D. Matchar 2000 Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis Am. J. Epidemiol. 151 1158 1171
68. Myers, E., Green, S., Lipkus, I., 2004. Pateint preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. In: Proceedings of the 21st International Papillomavirus Conference, 390.2 2004. Mexico City, Mexico.
69. M.A. Nobbenhuis J.M. Walboomers T.J. Helmerhorst 1999 Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study Lancet 354 20 25
70. D.M. Parkin F. Bray J. Ferlay P. Pisani 2005 Global cancer statistics CA Cancer J. Clin. 55 74 108
71. B.J. Quade J.J. Park C.P. Crum 1998 In vivo cyclin E expression as a marker for early cervical neoplasia Mod. Pathol. 11 1238 1246
72. A. Rao M. Chen B. Pham A. Tricco V. Gilca 2006 Cohort effects in dynamic models and their impact on vaccination programmes: an example from Hepatitis A BMC Infect. Dis. 6 174
73. Ries, L., Eisner, M., Kosary, C. et al., 2005. SEER cancer statistics review, 1975-2002. Bethesda, MD, National Cancer Institute, http://seer.cancer. gov/csr/1975_2002/.
74. M. Saint G. Gildengorin G.F. Sawaya 2005 Current cervical neoplasia screening practices of obstetrician/gynecologists in the US Am. J. Obstet. Gynecol. 192 2 414 21
75. G.D. Sanders A.V. Taira 2003 Cost Effectiveness of a Potential Vaccine for Human Papillomavirus Emerg. Infect. Dis. 9 37 48
76. X. Sastre-Garau I. Cartier N. Jourdan-Da Silva 2004 Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype Obstet. Gynecol. 104 751 755
77. J. Sellors J. Mahony J. Kaczorowski A. Lytwyn H. Bangura A. Lorincz 2000 Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada CMAJ 163 503 508
78. J. Sellors T. Kaczorowski J. Kaczorowski J. Mahony A. Lytwyn S. Chong 2002 Prevalence of infection with carcinogenic human papillomavirus among older women CMAJ 167 871 872
79. Stratton, K., Durch, J., Lawerence, R. (Eds.), 2000. Committee to Study Priorities for Vaccine Development. Institute of Medicine. Vaccines for the 21st Century: A Tool for Decisionmaking. Appendix 11. Human Papillomavirus, pp. 213-222. National Academy Press, Washington.
80. Surveillance, Epidemiology, and End Results (SEER) Program. 2004. (http://www.seer.cancer.gov) SEER*Stat Database: Survival - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
81. US Bureau of Labor Statistics, 2002. Statistical Abstracts of the United States: Consumer Price Index. National Center for Health Statistics, Washington.
82. L.L. Villa R.L.R. Costa C.A. Petta R.P. Andrade K.A. Ault 2005 Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-conrolled multicentre phase II e¢ cacy trial Lancet Oncol. 6 271 278
83. K.-L. Wallin F. Wiklund T. Ångström 1999 Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer N. Engl. J. Med. 341 1633 1638
84. Weinstein, M., 1996. From cost-effectiveness ratios to resource allocation: Where to draw the line? In: Sloan, F. (Ed.), Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies, pp. 77-97. Cambridge University Press, New York.
85. M.C. Weinstein B. O'Brien J. Hornberger J. Jackson M. Johannesson C. McCabe B.R. Luce 2003 Principles of good decision analytic modeling Value Health 6 9 17
86. L. Wenzel I. DeAlba R. Habbal B.C. Kluhsman D. Fairclough 2005 Quality of life in long-term cervical cancer survivors Gynecol. Oncol. 97 2 310 317
87. L. Westergaard M. Norgaard 1981 Severe cervical dysplasia. Control by biopsies or primary conization? A comparative study Acta Obstet. Gynecol. Scand. 60 549 554
88. R.L. Winer N.B. Kiviat J.P. Hughes D.E. Adam S.K. Lee 2005 Development and duration of human papillomavirus lesions, after initial infection J. Infect. Dis. 191 731 738
89. Wolfram, S., 2005. The Mathematica Book, 5th edn. Wolfram Media, Wolfram Research, Inc., Champaign.